Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Effects of empagliflozin according to background angiotensin receptor-neprilysin inhibitor and mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction (SUGAR-DM-HF)

The sodium-glucose cotransporter 2 inhibitor empagliflozin reduces left ventricular (LV) volumes in heart failure with reduced ejection fraction (HFrEF). Whether this effect is additive to optimal background guideline-recommended therapy is unknown. To evaluate the effects of empagliflozin according to key...

M. Lee, C. Berry, R. Campbell et al. · 0 citations
Open access Aug 2026

Targeted Assessment in High-Risk Patients With Diabetes to Identify Undiagnosed Heart Failure (TARTAN-HF).

BACKGROUND Heart failure (HF) is a common cardiovascular complication of diabetes. Early identification of unrecognized HF enables initiation of disease-modifying therapies. International diabetes and HF clinical practice guidelines are inconsistent with respect to recommendations for screening for HF in people with di...

D. Taylor-Sweet, M. Petrie, Gemma Mckinley et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.